Assenagon Asset Management
FULC icon

Assenagon Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Assenagon Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
835,204
-358,669
-30% -$2.18M ﹤0.01% 766
2026
Q1 		$9.16M Buy
+1,193,873
New +$11.1M 0.01% 479
2024
Q4 		– Sell
-340,495
Closed -$1.22M – 1373
2024
Q3 		$1.22M Sell
340,495
-156,961
-32% -$1.16M ﹤0.01% 1094
2024
Q2 		$3.08M Buy
+497,456
New +$3.77M 0.01% 766

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management's FULC Position: Q2 2026 in Review

Assenagon Asset Management reduced its Fulcrum Therapeutics (FULC) stake by 30% in Q2 2026, selling an estimated $2.18M and leaving 835,204 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #766.

Assenagon Asset Management first reported a position in FULC in Q2 2024 and has held it in 4 quarters since. The position peaked at $9.16M in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Assenagon Asset Management held 835,204 shares of Fulcrum Therapeutics worth $3.06M as of Q2 2026.
  • Assenagon Asset Management sold 358,669 Fulcrum Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Fulcrum Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #766 holding.
  • Assenagon Asset Management first reported a position in Fulcrum Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Assenagon Asset Management's Fulcrum Therapeutics position peaked at $9.16M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.